ValuEngine lowered shares of Exelixis (NASDAQ:EXEL) from a sell rating to a strong sell rating in a research report report published on Monday morning, ValuEngine reports.

Several other research firms have also commented on EXEL. Cowen set a $25.00 price target on Exelixis and gave the stock a buy rating in a research report on Wednesday, July 31st. Stifel Nicolaus boosted their price target on Exelixis from $22.00 to $23.00 and gave the stock a hold rating in a research report on Thursday, August 1st. Zacks Investment Research raised Exelixis from a hold rating to a buy rating and set a $23.00 price target for the company in a research report on Tuesday, August 6th. Finally, BidaskClub lowered Exelixis from a hold rating to a sell rating in a research report on Wednesday, August 28th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. Exelixis currently has an average rating of Hold and a consensus price target of $28.57.

Shares of EXEL stock opened at $19.57 on Monday. Exelixis has a twelve month low of $13.42 and a twelve month high of $25.31. The stock has a market capitalization of $5.87 billion, a price-to-earnings ratio of 15.25 and a beta of 2.04. The stock has a fifty day simple moving average of $20.07 and a two-hundred day simple moving average of $21.15. The company has a current ratio of 8.64, a quick ratio of 8.53 and a debt-to-equity ratio of 0.02.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $0.25 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.23 by $0.02. The firm had revenue of $240.28 million during the quarter, compared to analyst estimates of $226.97 million. Exelixis had a return on equity of 31.31% and a net margin of 70.52%. The business’s revenue for the quarter was up 29.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.31 EPS. Research analysts predict that Exelixis will post 0.92 EPS for the current fiscal year.

In related news, Director George A. Scangos sold 40,000 shares of the company’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $21.58, for a total transaction of $863,200.00. Following the transaction, the director now directly owns 1,168,031 shares of the company’s stock, valued at approximately $25,206,108.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director George Poste sold 25,000 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $20.50, for a total value of $512,500.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 367,522 shares of company stock valued at $7,640,875. Corporate insiders own 4.50% of the company’s stock.

A number of large investors have recently made changes to their positions in the stock. BlackRock Inc. increased its position in Exelixis by 1.0% during the 1st quarter. BlackRock Inc. now owns 30,875,633 shares of the biotechnology company’s stock valued at $734,839,000 after buying an additional 290,882 shares in the last quarter. AQR Capital Management LLC increased its position in Exelixis by 46.4% during the 1st quarter. AQR Capital Management LLC now owns 15,852,556 shares of the biotechnology company’s stock valued at $377,291,000 after buying an additional 5,021,444 shares in the last quarter. Renaissance Technologies LLC increased its position in Exelixis by 40.7% during the 2nd quarter. Renaissance Technologies LLC now owns 13,454,473 shares of the biotechnology company’s stock valued at $287,522,000 after buying an additional 3,889,200 shares in the last quarter. JPMorgan Chase & Co. increased its position in Exelixis by 10.1% during the 1st quarter. JPMorgan Chase & Co. now owns 9,938,985 shares of the biotechnology company’s stock valued at $236,548,000 after buying an additional 910,147 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in Exelixis by 20.7% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 6,143,165 shares of the biotechnology company’s stock valued at $131,279,000 after buying an additional 1,051,976 shares in the last quarter. 77.39% of the stock is currently owned by institutional investors.

Exelixis Company Profile

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Read More: Book Value Per Share – BVPS

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.